Will GWAS eventually allow the identification of genomic biomarkers for COVID-19 severity and mortality?

被引：9

作者：

Colona, Vito Luigi ^{[1
]}

Biancolella, Michela ^{[2
]}

Novelli, Antonio ^{[3
]}

Novelli, Giuseppe ^{[1
,4
,5
]}

机构：

[1] Tor Vergata Univ Rome, Dept Biomed & Prevent, Rome, Italy

[2] Tor Vergata Univ Rome, Dept Biol, Rome, Italy

[3] IRCCS Bambino Gesu Childrens Hosp, Lab Med Genet, Rome, Italy

[4] IRCCS Neuromed, Pozzilli, IS, Italy

[5] Univ Nevada, Sch Med, Dept Pharmacol, Reno, NV 89557 USA

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2021年 / 131卷 / 23期

关键词：

D O I：

10.1172/JCI155011

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

GWAS involve testing genetic variants across the genomes of many individuals to identify genotype-phenotype associations. GWAS have enabled the identification of numerous genomic biomarkers in various complex human diseases, including infectious ones. However, few of these studies are relevant for clinical practice or at the bedside. In this issue of the JCI, Nakanishi et al. characterized the clinical implications of a major genetic risk factor for COVID-19 severity and its age-dependent effect, using individual-level data in a large international multicenter consortium. This study indicates that a common COVID-19 genetic risk factor (rs10490770) associates with increased risks of morbidity and mortality, suggesting potential implications for future clinical risk management. How can the genomic biomarkers identified by GWAS be associated with the clinical outcomes of an infectious disease? In this Commentary, we evaluate the advantages and limitations of this approach.

引用

页数：4

共 25 条

[1] X-linked recessive TLR7 deficiency in ∼1% of men under 60 years old with life-threatening COVID-19 [J].

Asano, Takaki ;

Boisson, Bertrand ;

Onodi, Fanny ;

Matuozzo, Daniela ;

Moncada-Velez, Marcela ;

Renkilaraj, Majistor Raj Luxman Maglorius ;

Zhang, Peng ;

Meertens, Laurent ;

Bolze, Alexandre ;

Materna, Marie ;

Korniotis, Sarantis ;

Gervais, Adrian ;

Talouarn, Estelle ;

Bigio, Benedetta ;

Seeleuthner, Yoann ;

Bilguvar, Kaya ;

Zhang, Yu ;

Neehus, Anna-Lena ;

Ogishi, Masato ;

Pelham, Simon J. ;

Le Voyer, Tom ;

Rosain, Jeremie ;

Philippot, Quentin ;

Soler-Palacin, Pere ;

Colobran, Roger ;

Martin-Nalda, Andrea ;

Riviere, Jacques G. ;

Tandjaoui-Lambiotte, Yacine ;

Chaibi, Khalil ;

Shahrooei, Mohammad ;

Darazam, Ilad Alavi ;

Olyaei, Nasrin Alipour ;

Mansouri, Davood ;

Palabiyik, Figen ;

Ozcelik, Tayfun ;

Novelli, Giuseppe ;

Novelli, Antonio ;

Casari, Giorgio ;

Aiuti, Alessandro ;

Carrera, Paola ;

Bondesan, Simone ;

Barzaghi, Federica ;

Rovere-Querini, Patrizia ;

Tresoldi, Cristina ;

Franco, Jose Luis ;

Rojas, Julian ;

Reyes, Luis Felipe ;

Bustos, Ingrid G. ;

Arias, Andres Augusto ;

Morelle, Guillaume .

SCIENCE IMMUNOLOGY, 2021, 6 (62)

[2] Autoantibodies neutralizing type I IFNs are present in ∼4% of uninfected individuals over 70 years old and account for ∼20% of COVID-19 deaths [J].

Bastard, Paul ;

Gervais, Adrian ;

Le Voyer, Tom ;

Rosain, Jeremie ;

Philippot, Quentin ;

Manry, Jeremy ;

Michailidis, Eleftherios ;

Hoffmann, Hans-Heinrich ;

Eto, Shohei ;

Garcia-Prat, Marina ;

Bizien, Lucy ;

Parra-Martinez, Alba ;

Yang, Rui ;

Haljasmagi, Liis ;

Migaud, Melanie ;

Sarekannu, Karita ;

Maslovskaja, Julia ;

de Prost, Nicolas ;

Tandjaoui-Lambiotte, Yacine ;

Luyt, Charles-Edouard ;

Amador-Borrero, Blanca ;

Gaudet, Alexandre ;

Poissy, Julien ;

Morel, Pascal ;

Richard, Pascale ;

Cognasse, Fabrice ;

Troya, Jesus ;

Trouillet-Assant, Sophie ;

Belot, Alexandre ;

Saker, Kahina ;

Garcon, Pierre ;

Riviere, Jacques G. ;

Lagier, Jean-Christophe ;

Gentile, Stephanie ;

Rosen, Lindsey B. ;

Shaw, Elana ;

Morio, Tomohiro ;

Tanaka, Junko ;

Dalmau, David ;

Tharaux, Pierre-Louis ;

Sene, Damien ;

Stepanian, Alain ;

Megarbane, Bruno ;

Triantafyllia, Vasiliki ;

Fekkar, Arnaud ;

Heath, James R. ;

Franco, Jose Luis ;

Anaya, Juan-Manuel ;

Sole-Violan, Jordi ;

Imberti, Luisa .

SCIENCE IMMUNOLOGY, 2021, 6 (62)

[3]

Colona VL, 2021, HUM GENOMICS, V15, DOI 10.1186/s40246-021-00356-x

[4] Do monogenic inborn errors of immunity cause susceptibility to severe COVID-19? [J].

Cotsapas, Chris ;

Saarela, Janna ;

Farmer, Jocelyn R. ;

Scaria, Vinod ;

Abraham, Roshini S. .

JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (14)

[5] The ABO blood group system and Plasmodium falciparum malaria [J].

Cserti, Christine M. ;

Dzik, Walter H. .

BLOOD, 2007, 110 (07) :2250-2258

[6] ABO blood group predisposes to COVID-19 severity and cardiovascular diseases [J].

Dai, Xiaofeng .

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (13) :1436-1437

[7] Genetics Insight for COVID-19 Susceptibility and Severity: A Review [J].

Fricke-Galindo, Ingrid ;

Falfan-Valencia, Ramces .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[8]

Gaebler C., 2020, Nature, DOI [10.1038/s41586-020-2008-3, 10.1038/s41586-021-03207-w]

[9] Characterization of the human ABO genotypes and their association to common inflammatory and cardiovascular diseases in the UK Biobank [J].

Hoglund, Julia ;

Karlsson, Torgny ;

Johansson, Therese ;

Ek, Weronica E. ;

Johansson, Asa .

AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (11) :1350-1362

[10] Genetic variants are identified to increase risk of COVID-19 related mortality from UK Biobank data [J].

Hu, Jianchang ;

Li, Cai ;

Wang, Shiying ;

Li, Ting ;

Zhang, Heping .

HUMAN GENOMICS, 2021, 15 (01)

← 1 2 3 →